Last $2.08 USD
Change Today -0.01 / -0.48%
Volume 1.6M
ATRS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Open
$2.09
Previous Close
$2.09
Day High
$2.14
Day Low
$2.01
52 Week High
10/14/13 - $5.15
52 Week Low
07/28/14 - $1.87
Market Cap
271.4M
Average Volume 10 Days
890.4K
EPS TTM
$-0.23
Shares Outstanding
130.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; Meda Pharmaceuticals; Pfizer Inc; Population Council; and LEO Pharma. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

60 Employees
Last Reported Date: 03/13/14
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2013.

antares pharma inc (ATRS) Key Developments

Antares Pharma Inc. Announces Promotion of Robert F. Apple to Chief Operating Officer

Antares Pharma Inc. announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. The company also announced that a retained search has begun to fill the position of Chief Financial Officer. Until the position is filled, Mr. Apple will continue to serve as the company's Chief Financial Officer as he has since he joined Antares Pharma in 2006. Mr. Apple joined the Company in February 2006 as Senior Vice President and Chief Financial Officer and was promoted to Executive Vice President, Chief Financial Officer and President of the Parenteral Products Group in 2008.

Antares Pharma Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM

Antares Pharma Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Eamonn P. Hobbs, Chief Executive Officer, President, Independent Director, Member of Audit Committee and Member of Governance & Nominating Committee, Robert F. Apple, Chief Financial Officer, Chief Accounting Officer, President of the Parenteral Products Division, Executive Vice President and Secretary.

Antares Pharma Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Antares Pharma Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported product sales of $3,360,000 compared to $4,513,000 a year ago. Total revenue was $6,327,000 compared to $5,838,000 a year ago. Operating loss was $9,091,000 compared to $5,131,000 a year ago. Net loss was $9,098,000 or $0.07 per basic and diluted share compared to $5,103,000 or $0.04 per basic and diluted share a year ago. For the six months, the company reported product sales of $5,165,000 compared to $7,005,000 a year ago. Total revenue was $11,529,000 compared to $10,366,000 a year ago. Operating loss was $17,899,000 compared to $8,534,000 a year ago. Net loss was $17,892,000 or $0.14 per basic and diluted share compared to $8,512,000 or $0.07 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.08 USD -0.01

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardica Inc $1.29 USD +0.10
Cerus Corp $4.01 USD +0.01
Pluristem Therapeutics Inc $2.94 USD +0.01
SurModics Inc $18.72 USD +0.01
Uroplasty Inc $2.69 USD +0.08
View Industry Companies
 

Industry Analysis

ATRS

Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit www.antarespharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.